Surrozen, Inc. (SRZN) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Surrozen reported revenue of $3.5M, down 67.4% from $10.7M the year before. Net income was -$242.0M (a -6960.8% net margin), or -$32.37 per diluted share. Operating margin was -1210.6%. Operating activities generated -$30.2M of cash, leaving -$30.3M of free cash flow. At fiscal year end, Surrozen held $98.7M in total assets against $286.5M in total liabilities, including $89.2M of cash and equivalents.
Open the full interactive Surrozen financials → Quarterly statements, key ratios, valuation history and price charts.
Surrozen Key Stats
| Share Price | $23.51 |
|---|---|
| Market Cap | $544,162 |
| Revenue YoY Growth | -67.4% |
| 52-Week Range | $11.80 – $34.13 |
| Shares Outstanding | 11,663 (basic, 2026 Q2) |
Surrozen Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $12.5M | $0 | $10.7M | $3.5M |
| Operating Income | -$54.4M | -$44.3M | -$45.8M | -$25.5M | -$42.1M |
| Pre-Tax Income | -$54.6M | -$36.0M | -$43.0M | -$63.6M | -$242.0M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$54.6M | -$36.0M | -$43.0M | -$63.6M | -$242.0M |
| Diluted EPS | -$33.20 | -$15.60 | -$21.33 | -$21.67 | -$32.37 |
Surrozen Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $983,000 | $528,000 | $5.0M | $5.0M |
| Net Income | -$71.6M | -$183.2M | -$127.5M | $50.2M |
| Diluted EPS | -$8.36 | -$24.49 | -$11.65 | -$0.41 |
Surrozen Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $33.1M | $24.7M | $36.0M | $34.6M | $89.2M |
| Current Assets | $105.2M | $81.3M | $41.1M | $38.9M | $91.6M |
| Total Assets | $137.2M | $89.4M | $46.1M | $48.5M | $98.7M |
| Current Liabilities | $13.6M | $9.7M | $7.1M | $7.3M | $9.9M |
| Total Liabilities | $27.5M | $13.4M | $8.1M | $69.8M | $286.5M |
| Shareholders' Equity | $109.7M | $76.0M | $37.9M | -$21.4M | -$187.8M |
Surrozen Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$48.8M | -$44.1M | -$40.4M | -$17.6M | -$30.2M |
| Cash From Investing | -$77.7M | $38.3M | $51.7M | -$26,000 | -$128,000 |
| Cash From Financing | $124.6M | -$2.6M | $276,000 | $16.2M | $85.1M |
| Free Cash Flow | -$50.1M | -$44.8M | -$40.8M | -$17.6M | -$30.3M |
Figures from Surrozen's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Surrozen financials page for every line item.
Surrozen Company Profile
| Ticker | SRZN |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001824893 |
Frequently Asked Questions
What was Surrozen's revenue in fiscal 2025?
Surrozen (SRZN) reported revenue of $3.5M for fiscal 2025.
What is Surrozen's annual revenue history?
Surrozen's annual revenue by fiscal year: 2021: $0; 2022: $12.5M; 2023: $0; 2024: $10.7M; 2025: $3.5M.
What was Surrozen's net income in fiscal 2025?
Surrozen reported net income of -$242.0M for fiscal 2025.
What was Surrozen's earnings per share (EPS) in fiscal 2025?
Surrozen's diluted EPS was -$32.37 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Surrozen generate in fiscal 2025?
Surrozen generated -$30.3M of free cash flow in fiscal 2025.
What was Surrozen's revenue last quarter?
In its most recent reported quarter (2026 Q2), Surrozen reported revenue of $5.0M.
How many shares of Surrozen are outstanding?
Surrozen reported a weighted average of 11,663 basic shares outstanding in 2026 Q2.
What is Surrozen's market cap?
Based on its latest closing price, Surrozen (SRZN) has a market capitalization of about $544,162.
When does Surrozen's fiscal year end?
Surrozen's fiscal year end, as registered with the SEC, is December 31.
Where is Surrozen headquartered?
Surrozen lists its business address in South San Francisco, California in its SEC filings.
Surrozen Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →